Redeye provides an update following Paxman’s Q1 2025 report. While the results fell short of our expectations, we maintain a positive view on Paxman’s outlook and argue that better and more interesting quarters are ahead of us. We have made some downward revisions based on the report; however, we now also include the CIPN segment in our forecasts, resulting in an upwardly revised fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/